Is Thailand re-banning cannabis? Investors are asking the wrong question

Every capital allocator looking at Thailand asks the same question first: will this get banned. It is the wrong question. The regulatory direction has already been set, it points toward entrenchment of a medical framework, and the risk that actually erodes returns is not prohibition. It is oversupply.

Start with what already happened, because it is public and it is settled. Since 25 June 2025, cannabis flower has been reclassified as a "controlled herb" under Thai traditional-medicine law Certain. Retail sale now requires a PT 33 prescription. Recreational sale is not legal. Cannabis itself is not on the narcotics list, but extracts above 0.2% THC are Category 5 narcotics, which draws a sharp legal line between flower and concentrate that every operator and every investor needs to hold in their head separately.

That reclassification did real damage to the shop count. Of roughly 18,433 shops operating at the market's peak, about 7,297 had closed by early 2026, leaving approximately 11,136 still operating Certain. If you only look at that number, it reads like a slow-motion ban. It is not. It is a filter.

Recriminalization is not the live risk

Our read, based on the direction of travel rather than any single announcement, is that recriminalization risk is low Likely. Thailand is not walking cannabis back into the narcotics schedule. It is walking it into a medical-access framework and tightening the plumbing around that framework: prescriptions, herb classification, a reported Cannabis and Hemp Act moving to codify the medical structure into statute. Every regulatory action since mid-2025 has been about who may sell and under what documentation, not about whether cannabis may exist in commerce at all.

This matters for how you price the tail risk. A ban scenario is the one that shows up in generic country-risk decks because it is legible and dramatic. It is also the one least supported by the actual sequence of events here. The government has spent political capital building the prescription and herb-classification apparatus. Regimes do not usually build elaborate administrative machinery for a category they intend to delete.

What entrenchment actually does to the market

Here is the investor-relevant translation of "medical framework entrenchment": it does not shrink the addressable market to zero, and it does not freeze it either. It formalizes who can compete, raises the compliance floor, and removes the operators who could not survive under prescription-gated retail. That is precisely what the shop closures represent - not a market being switched off, but a market being sorted into operators who can run a licensed, PT 33-compliant business and operators who could not.

The consequence for anyone underwriting an entry is that the surviving base is a different, more durable population than the peak-era shop count implied. The national market value under this entrenched structure is Likely, reconstructed in the report. the figure is in the report → What you can state without redaction is the shape of the risk: it is a licensing and compliance risk, not an existential one.

The downside that actually shows up in a model

If the framework is entrenching rather than reversing, the live downside scenario is not a ban - it is loosening combined with oversupply. GACP-licensed cultivation farms already number 217 Certain and are growing at roughly ten a week. No Thai authority publishes national cultivation area, production tonnage, or lab-testing throughput Certain, which means capacity is expanding faster than anyone can verify it against demand. That is the triple absence that should worry an investor far more than a recriminalization headline: cultivation area, output, and testing volume are all unmeasured and all growing.

Combine an entrenched but still-immature licensing regime with capacity additions nobody is counting, and the mechanical result is price compression, not market collapse. Margins get squeezed from the supply side while the demand side stays gated by prescription requirements. That dynamic, not a prohibition scenario, is what should sit at the center of a Thailand cannabis underwriting model. The three-layer value stack, the grey-market share of dispensary flower, and the production-tonnage figures that would let you size that compression precisely are redacted here and reconstructed in the report Likely. see the breakdown in the report →

Foreign capital sits inside the entrenchment, not outside it

The ownership structure reinforces the same read. Foreign ownership of a licensed core entity is capped at 49%, extract production is barred to foreigners outright, and the nominee shortcut some early entrants used is now a prosecuted Section 36 crime Certain. None of that is new since the framework tightened, and none of it has moved further against foreign capital. What has stayed open, and stayed legal, is participation through a genuine Thai-majority joint venture plus non-equity routes: offtake agreements, toll-manufacturing arrangements, IP and brand licensing, and financing structures. A regime intent on squeezing foreign capital out entirely does not usually leave that many structured doors open. It leaves open exactly the doors consistent with wanting capital in, discipline enforced.

How we know this

This read is built from direct exposure to the licensing and retail environment, not from following the news cycle: 850+ dispensaries visited across the country, including 650 in Bangkok, 100+ owner and operator interviews spanning ten-plus nationalities, 30+ farm operator conversations, and the firm's own completion of the full legal licensing process first-hand. That is what grounds the call that entrenchment, not reversal, is the operative direction - and why the risk worth modeling is compression, not a ban.